Product Description
Mechanisms of Action: GR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Canada | Chile | China | Denmark | Ecuador | Egypt | Germany | Greece | Ireland | Italy | Jordan | Korea | Mexico | Morocco | New Zealand | Norway | Pakistan | Peru | Philippines | Portugal | Spain | Switzerland | Taiwan | Tunisia | Ukraine | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|